# MEDI-FIRST- bacitracin zinc, neomycin sulfate, polymyxin b sulfate ointment Orazen Inc

Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

-----

# MEDI-FIRST PLUS Triple Antibiotic Ointment

# Active ingredients

(in each gram)

Bacitracin zinc 400 units

Neoycin sulfate equivalent to 3.5 mg of neomycin base

Polymyxin B sulfate 5,000 units

# **Purpose**

First Aid antibiotic

First Aid antibiotic

First Aid antibiotic

#### Uses

First aid to help prevent infection in minor cuts, scrapes, and burns

# Warning

# For external use only.

#### Do not use

- in the eyes
- internally
- over large areas of the body
- if you are allergic to any of the ingredients
- longer than 1 week unless directed by a doctor

### Ask a doctor before use

• in case of deep puncture wounds, animal bites or serious burns.

# Stop use and ask a doctor if

- the condition persists or gets worse
- a rash or other allergic reaction develops

# Keep out of reach of children.

If swallowed, get medical help or contact a Poison Control Center immediately.

#### **Directions**

- clean the affected area
- apply a small amount of this product (an amount equal to the surface area of the tip of a finger) on the area 1 to 3 times daily
- may be covered with a sterile bandage

## Other information

- store at room temperature (59°-86°F) (do not freeze)
- tamper evident. Do not use if packet is torn, cut or opened.

# Inactive ingredients

mineral oil, petrolatum, water

# Questions or comments?

1-800-634-7680

# Triple Antibiotic Ointment

NET WT. 1/57 oz (0.5 g) Packet


The state of the s	COURSE OF THE PROPERTY OF THE	
Active ingredients (in each	gram)	Purposes
Bacitracin zinc 400 units		First aid antibiotic
Neomycin sulfate		
(equivalent to 3.5 mg of neor	nycin base)	First aid antibiotic
Polymyxin B sulfate 5000 units		First aid antibiotic
Mfg. for Medique Products	Store at room te	mperature (59°-86°F) (do not freeze)
Fort Myers, FL 33967 USA		Tamper Evident Sealed Packet
1,00		

Uses First aid to help prevent infection in minor cuts, scrapes, and burns

Warnings For external use only. Do not use ■ in the eyes ■ internally ■ over large areas of the body ■ if you are allergic to any of the ingredients ■ longer than 1 week unless directed by a doctor. Ask a doctor before use ■ in case of deep puncture wounds, animal bites or serious burns. Stop use and ask a doctor if ■ the condition persists or gets worse ■ a rash or other allergic reaction develops Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center immediately.

Directions ■ clean the affected area ■ apply a small amount of this product (an amount equal to the surface area of the tip of a finger) on the area 1 to 3 times daily ■ may be covered with a sterile bandage.

**Retain Carton for Complete Product Information** 



# **MEDI-FIRST**

bacitracin zinc, neomycin sulfate, polymyxin b sulfate ointment

Product Information			
Product Type	HUMAN OTC DRUG	Item Code (Source)	NDC:71927-017
Route of Administration	TOPICAL		

Active Ingredient/Active Moiety			
Ingredient Name	Basis of Strength	Strength	
BACITRACIN ZINC (UNII: 89Y4M234ES) (BACITRACIN - UNII:58H6RW052I)	BACITRACIN	400 [USP'U] in 1 g	
NEOMYCIN SULFATE (UNII: 057Y626693) (NEOMYCIN - UNII:116QD7X297)	NEOMYCIN	0.0035 g in 1 g	
POLYMYXIN B SULFATE (UNII: 19371312D4) (POLYMYXIN B - UNII: J2VZ 07J96K)	POLYMYXIN B	5000 [USP'U] in 1 g	

Inactive Ingredients			
Strength			
PETROLATUM (UNII: 4T6H12BN9U)			
WATER (UNII: 059QF0KO0R)			

P	Packaging			
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:71927-017- 04	25 in 1 BOX	02/17/2023	
1	NDC:71927-017- 01	0.5 g in 1 POUCH; Type 0: Not a Combination Product		

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
OTC monograph final	part333B	02/17/2023	

# **Labeler -** Orazen Inc (080916640)

Revised: 2/2023 Orazen Inc